The Laser in Pseudoexfoliation (LIP) Study

Phase 4

Withdrawn

• Conditions: Glaucoma

• Registration Number: NCT01704989
• Lead Sponsor: Nova Scotia Health Authority

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-9-18
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - Evidence of PXF material on the anterior chamber structures by slit lamp<br> biomicroscopy.<br><br> - An open drainage angle with no irido-trabecular contact on non-indentation<br> gonioscopy in primary position trabecular meshwork visible over 360 degrees.<br><br> - Ocular hypertension or glaucoma deemed to require treatment by the attending<br> clinician.<br><br> - A decision to treat has been made by a Consultant Glaucoma Specialist.<br><br> - Age over 18 years and able to provide informed consent.<br><br>Exclusion Criteria:<br><br> - Advanced glaucoma as determined by EMGT criteria 1: visual field loss mean deviation<br> worse than -12 dB in the better or -15 dB in the worse eye.<br><br> - Co-existing other secondary glaucoma (e.g. pigment dispersion syndrome, rubeosis<br> etc) or angle closure glaucoma.<br><br> - History of retinal ischaemia, macular oedema or diabetic retinopathy.<br><br> - Age-related macular degeneration with neovascularisation or geographic atrophy and<br> VA worse than 6/36.<br><br> - Any previous intra-ocular surgery, except uncomplicated phacoemulsification at least<br> one year before.* Medically unfit for completion of the trial.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of drops (and surgical interventions) needed to reach target IOP.;Percentage success

Secondary Outcome Measures

Name	Time	Method
Correlation of angle pigment grade with IOP reduction from SLT;Comparison of percentage success and number of drops in current study with the equivalent results of patients with POAG in the LiGHT study;Number of progressing patients in each study arm (SLT or medical therapy) in terms of visual field loss and HRT.